AJANTPHARMNSEAjanta Pharma Limited· PharmaceuticalsMediumNeutral
Announced Tue, 7 Apr · 11:25 IST

YOGESH M. AGRAWAL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹2759.00
prior close
₹2733.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.0-0.1-0.2-2.0-0.3+1.6+4.9+4.5+1.1+1.5+11.3+7.6+20.2
Up moveDown movePending
AI summary

Yogesh M. Agrawal, on behalf of promoters and promoter group of Ajanta Pharma, has submitted a declaration to the exchanges confirming that no new encumbrances (pledges) on shares were created during the financial year ended 31st March 2026, beyond those already disclosed. This is a routine regulatory filing under SEBI takeover regulations requiring promoters to periodically confirm their pledge status. The declaration essentially states a 'no change' position regarding share pledging by the promoter group.

Likely market impact

This is a neutral-to-slightly positive disclosure for investors, as it confirms promoters have not increased their pledged shares, which could otherwise signal potential stress or dilution risk. No immediate impact on the stock expected.